Gulfem Guler
Vice President, Translational Research ClearNote Health
Seminars
Wednesday 7th October 2026
Cancer Biology Through 5hmC Liquid Biopsy: From Early Detection to Drug Development
8:30 am
- 5hmC is an epigenetic mark enriched at active gene bodies, enhancers, and promoters transitioning to an active state. Analysis of 5hmC in cell-free DNA therefore provides a window into active disease biology directly from blood
- Genome-wide 5hmC profiling with ClearNote Health’s Virtuoso epigenomic platform enables cancer detection, subtype classification, treatment response prediction, and longitudinal disease monitoring with a single, liquid biopsy-based assay
- Clinical evidence across lung, prostate, colorectal, and pancreatic cancers supports applications spanning early detection and drug development, establishing 5hmC profiling by Virtuoso as a versatile epigenomic tool across the oncology pipeline
